Join
Live feed
·
PRReleasevia Quantisnow
Monte Rosa Therapeutics Inc. logo

Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk

ByQuantisnow·Wall Street's wire, on your screen.
GLUE· Monte Rosa Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GLUE (Monte Rosa Therapeutics Inc.) and more on Quantisnow.